![]() |
|
|
Vol. 285, Issue 1, 127-134, April 1998
Unidad de Hepatología Experimental (M.I.G., M.T.D., R.J., J.V.C., M.J.G.-L.), Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain; and Servicio de Cirugía (R.F., R.T.), Hospital General de Valencia, Spain
| |
Abstract |
|---|
|
|
|---|
The effects of oncostatin M on the expression of different cytochrome
P450 (CYP) isozymes has been investigated in human hepatocytes. The
dose-response and time-course analyses of effects on CYP1A2 and CYP3A4
isozymes revealed that maximal inhibition was reached after 48 hr of
exposure of human hepatocytes to 25 units/ml oncostatin M. Reductions
in CYP1A2 and CYP3A4 activity produced by oncostatin M correlated with
decreases in protein content, de novo protein synthesis and
specific mRNA levels, thus suggesting that oncostatin M could
down-regulate CYP expression at the transcriptional level. The
inhibitory potency of oncostatin M on CYP expression was compared with
that of other cytokines belonging to the interleukin-6 receptor family
(interleukin-6, interleukin-11 and leukemia inhibitory factor), and
interferon-
, which is recognized to inhibit human CYP expression,
and granulocyte colony-stimulating factor, a cytokine that shares
structural homology with the interleukin-6 family but has a different
transduction signal. Maximal reductions in CYP1A2 activity were reached
after 48 hr of treatment with cytokines. At that time, oncostatin M
showed the highest inhibitory effects on CYP1A2 activity (38% of
control), followed by interferon (49% of control) and interleukin-6
(60% of control), whereas minor effects were produced by the other
cytokines (74-80%). Comparable decreases were observed for CYP2A6,
CYP2B6 and CYP3A4 activities. Enzymatic activity and de novo
protein synthesis of 3-methylcholanthrene-induced CYP1A2 and
dexamethasone-induced CYP3A4 were also reduced to a much greater extent
by oncostatin M than by other cytokines. The results show that
oncostatin M is the most effective cytokine in down-regulating CYP
isozymes in human hepatocytes, and its effects were evident even after
removal of the cytokine from the culture medium.
| |
Introduction |
|---|
|
|
|---|
Profound
systemic and hepatic functional changes are derived from the
inflammatory response of a host to insults of traumatic, infectious or
immune origin (Kushner, 1982
). This response is characterized in
the liver by increases in synthesis and secretion of acute-phase
proteins, alterations of intermediate metabolism and inhibition of
xenobiotic biotransformation (Koj, 1985
; Kushner and Mackiewicz, 1987
;
Richards and Gauldie, 1994
). The decrease in the rate of drug
metabolism during the inflammatory reaction arises from the reduced
activity of specific CYP isoenzymes (Morgan, 1993
; Shedlofsky et
al., 1994
). These effects are reproduced after treatment of
laboratory animals with immunoactivators, including cytokines and
cytokine-releasing agents (Ghezzi et al., 1985
; Craig
et al., 1990
; Ansher et al., 1992
; Chen
et al., 1992
). Despite the widely accepted belief that
cytokines can inhibit the CYP system in vivo, the mechanism
of this effect is largely unknown and could be mediated or influenced
by other cytokines or factors either released or coadministered during
the inflammation process.
In vitro studies with hepatic cells, and in particular human
hepatocyte cultures, offer defined systems for studying the direct effects of individual cytokines on the regulation of hepatic CYP expression and activity in man. IL-6 (Williams et al., 1991
;
Abdel-Razzak et al., 1993
; Fukuda and Sassa, 1994
; Clark
et al., 1995
), IL-1
(Barker et al., 1992
;
Abdel-Razzak et al., 1993
; Clark et al., 1995
;
Muntané-Relat et al., 1995
) and TNF-
(Abdel-Razzak
et al., 1993
; Chen et al., 1995
; Muntane-Relat
et al., 1995
), the three major proinflammatory cytokines,
down-regulate CYP expression in rodent and human hepatic cells in
culture. It has also been shown that other cytokines, including IFN
(Donato et al., 1993a
, 1997
; Abdel-Razzak et al.,
1993
, Clark et al., 1995
) and TGF-
(Abdel-Razzak et
al., 1994
), can influence CYP isozymes in cultured hepatocytes.
OSM is a multifunctional cytokine that is structurally and functionally
related to IL-6 (Rose and Bruce, 1991
; Hibi et al., 1996
).
The overlapping biological effects of OSM and IL-6 in many cellular
systems have been explained by their sharing the same signal
transducing molecule gp130 (Gearing et al., 1992
; Liu
et al., 1992
; Kishimoto, et al., 1994
). OSM acts
on a wide variety of cells and elicits diversified biological responses
such as growth regulation of certain tumor and non-tumor-derived cell lines (Zarling et al., 1986
; Horn et al., 1990
),
induction of differentiation of several cell types (Rose and Bruce,
1991
; Brown et al., 1991
), low-density lipoprotein
up-regulation in liver cells (Grove et al., 1991
) and
acute-phase protein induction in hepatocytes (Richards et
al., 1992
). However, despite the available information on the
multiple hepatocellular functions of OSM, its effects on hepatic drug
metabolism remain unknown.
The present study was conducted to examine the potential
down-regulation by OSM of CYP expression. To this end, specific
monooxygenase activities for different CYP isozymes, de novo
CYP protein synthesis and specific mRNA expression were examined. The
effects of OSM have also been compared with those of IL-6 and IFN, two
cytokines with well-known depressing effect on CYP expression, as well
as with the other IL-6-related cytokines, IL-11 and LIF (Nicola, 1994
;
Kishimoto et al., 1994
; Hibi et al., 1996
), and
with G-CSF, a cytokine that shares structural homology with the IL-6
family but has a different transduction signal (Rose and Bruce, 1994
). The results indicate that OSM has very potent inhibiting effect on
human CYP expression in basal and induced hepatocytes and is even more
effective than other cytokines with demonstrated capacity to
down-regulate CYP proteins.
| |
Materials and Methods |
|---|
|
|
|---|
Materials.
Recombinant human OSM was obtained from Pharmigen
(San Diego, CA); recombinant human IL-6 was purchased from Menarini
Diagnostics (Florence, Italy); recombinant human IL-11, LIF and G-CSF
were from British Bio-technology Products (Oxon, UK); recombinant human IFN, 7-benzoxyresorufin, 7-ethoxyresorufin, collagenase and
-glucuronidase/arylsulfatase were purchased from Boehringer-Mannheim
(Mannheim, Germany); coumarin, 7-hydroxycoumarin, resorufin,
testosterone and MC were purchased from Sigma Chemical (St. Louis, MO);
DEX was obtained from Merck Sharp & Dohme (Alcalá de Henares,
Madrid); 6
-hydroxytestosterone was supplied by Steraloids (Wilton,
NH); trans-35S-label (specific activity, 1138 Ci/mmol) was obtained from ICN Pharmaceuticals (Costa Mesa, CA);
newborn calf serum was obtained from GIBCO (Paisley, UK); Ham's F-12
and Leibovitz L-15 culture media were from Flow (Irvine, UK); RPMI 1640 methionine-free medium was purchased from Seromed (Berlin, Germany);
and all other reagents used in this study were of analytical grade.
Isolation and culture of human hepatocytes.
Surgical liver
biopsies (1-5 g) were taken from patients undergoing cholecystectomy
after informed consent was obtained. Patients had no known liver
pathology, nor did they receive medication during the weeks before
surgery. None of the patients were habitual consumers of alcohol or
other drugs. A total of 11 liver biopsy samples (from four men and
seven women) were used. Patients' ages ranged from 33 to 70 years
(table 1). Human hepatocytes were isolated using a two-step perfusion technique (Gómez-Lechón et al., 1990
) and seeded onto 24-well or 3.5-cm-diameter
fibronectin-coated plates (3.6 µg/cm2) at a density of
8 × 104 cells/cm2 in an appropriate
volume of medium. Culture medium was Ham's F-12/Leibovitz L-15 (1/1,
v/v) supplemented with 2% newborn calf serum, 5 mM glucose, 50 units/ml penicillin, 50 µg/ml streptomycin, 0.2% bovine serum
albumin and 10
8 M insulin. Medium was changed 1 hr later
to remove unattached hepatocytes. By 24 hr, cultures were shifted to
serum-free medium.
|
Treatment of cultures. Cytokines were prepared as sterile solutions in culture medium containing serum and added directly to cultures. Treatments were started by 24 hr of culture after medium renewal, and control cells were run in parallel. For CYP induction experiments, MC and DEX were dissolved in dimethylsulfoxide and added to 24-hr-old cultured human hepatocytes at a final concentration of 2 and 1 µM, respectively (concentration of solvent in culture medium was 0.5% v/v).
Monooxygenase activity assays.
CYP1A2 and CYP2B2 activities
were assessed as 7-ethoxyresorufin-O-deethylation (Gonzalez, 1990
) and
7-benzoxyresorufin-O-debenzylation (Waxman et al., 1991
),
respectively. Activities were assayed in intact hepatocytes cultured on
24-well culture plates incubated with 8 µM 7-ethoxyresorufin or 15 µM 7-benzoxyresorufin, respectively, and the resorufin formed was
quantified fluorimetrically as previously described (Donato et
al., 1993b
). CYP2A6 activity (assessed as coumarin
7-hydroxylation, Yun et al., 1991
) was measured directly in
intact hepatocytes cultured on 24-well culture plates incubated with
100 µM coumarin for 30 min at 37°C, and the 7-hydroxycoumarin formed was quantified fluorometrically as described (Donato et al., 1997
). CYP3A4 activity (assessed as testosterone
6
-hydroxylation; Waxman et al., 1991
) was measured by
incubating intact hepatocytes cultured on 24-well plates for 30 min
with 300 µl of culture medium containing 250 µM testosterone.
Metabolites were extracted and analysed by HPLC as described (Donato
et al., 1993a
). Cellular protein was measured according to
the method of Lowry et al. (1951)
.
Analysis of CYP proteins. Polyclonal antibodies against recombinant CYP1A2 and CYP3A4 were kindly provided by Dr. F. P. Guengerich (Nashville, TN). For Western blot analysis, cellular lysates were obtained from human cultured hepatocytes incubated with cytokines for the indicated times and electrophoresed in a SDS-polyacrylamide gel (30 µg of protein/lane). Proteins were transferred to Immobilon membranes (Millipore), and sheets were sequentially incubated with goat antiserum raised against recombinant CYP1A2, rabbit antiserum raised against goat-IgG and with horseradish peroxidase-labeled rabbit-IgG, or with rabbit antiserum raised against recombinant CYP3A4 and horseradish peroxidase-labeled rabbit-IgG. The substrate for the peroxidase enzyme was 0.05% diaminobenzidine (w/v) and 0.001% H2O2 (v/v) in PBS. The relative intensities of the bands were estimated from densitometric analysis of the blot with an Image Analyzer (Visilog 4; Noesis Vision, Velizy, France).
For immunoprecipitation assays, hepatocytes stimulated with appropriate concentrations of cytokines for the indicated times were shifted to methionine-free RPMI-1640 medium and pulse-labeled for 4 hr with 50 µCi/ml of [35S]-methionine (trans 35S-label). Radiolabeled CYP isozymes present in the cellular lysate were immunoprecipitated with specific polyclonal antibodies against recombinant CYP1A2 and CYP3A4, subjected to SDS-polyacrylamide electrophoresis under reducing conditions and fluorography as described (Castell et al., 1990Analysis of mRNA by semiquantitative RT-PCR.
Total
cellular RNA was extracted and reverse transcribed as described
(Chomczynski and Sacchi, 1987
). For CYP3A4 cDNA amplification (Gonzalez
et al., 1988
), the forward primer was from 1353 to 1379 nt
(5'-CCT TAC ACA TAC ACA CCC TTT GGA AGT-3'), and the reverse primer was
from 1705 to 1734 nt (5'-AGC TCA ATG CAT GTA CAG AAT CCC CGG TTA-3')
and amplified a predicted 382-bp fragment. For CYP1A2 cDNA (Jaiswal
et al., 1986
), the forward and reverse primers 5'-AAC AAG
GGA CAC AAC GCT GAA T-3' and 5'-GGA AGA GAA ACA AGG GCT GAG T-3',
respectively, produced a predicted 453-bp fragment between position
1178 and 1630. In parallel, we analyzed G6PD (Persico et
al., 1986
) as an internal control for normalization. The forward
and reverse primers, 5'-AAG CCC GCC TCC ACC AAC TCA-3' and 5'-GGC ACC
CCA TCC CAC CTC TCA T-3', respectively, produced a predicted 236-bp
fragment between position 1293 and 1529. Diluted cDNA (3 µl) was
amplified in 30 µl of 10 mM Tris-HCl (pH 8.8) containing 50 mM KCl,
1.5 mM MgCl2, 0.1% Triton X-100, 60 µM concentration of
each deoxynucleotide triphosphate, 1 unit of DNA polymerase (Dynazyme
II, Finnzymes OY) and 0.2 µM concentration of each primer. Amplification was performed in a Peltier Thermal Cycler (PTC-100HB, MJ
Research) programmed for an initial denaturation of 4 min at 94°C,
followed by 27 cycles of 45 sec at 94°C, 45 sec at 58°C and 1 min
at 72°C and a final extension of 5 min at 72°C. Appropriate dilutions were empirically determined for each cDNA to ensure that the
resulting PCR product was derived only from the exponential phase of
the amplification. For quantitative analysis, aliquots of the PCR
reaction were subjected to electrophoresis on agarose gel, and the
products were visualized by ethidium bromide staining. The gel image
was analysed and quantified with the VisiLog Software Package (VISILOG
4).
Determination of nitrite concentration.
To determine the
amount of nitric oxide synthetized by hepatocytes, the culture
supernatants were assayed for nitrite, as a stable end product of
nitric oxide oxidation. Nitrite accumulation was measured in 96-well
plates by adding 100 µl of culture supernatant to 100 µl of Griess
reagent as described previously (Donato et al., 1997
).
Statistical analysis. Each experiment was done in at least three cell preparations from different donors. Data are shown as the mean ± S.D. Data were analyzed by using the Student's t test. Values of P < 0.05 were considered significant.
| |
Results |
|---|
|
|
|---|
Down-regulation of CYP1A2 and CYP3A4 expression in human hepatocytes by OSM. The CYP1A2 and CYP3A4 activities of freshly isolated hepatocytes (2.49 ± 0.62 and 136 ± 33 pmol/mg/min, respectively; n = 6) decreased during the first 24 hr in culture to 1.62 ± 0.46 and 95 ± 24 pmol/mg/min, respectively (n = 7). After this decrease, probably due to the adaptation of cells to culture conditions, the enzyme was stable up to 96 hr of culture. Incubation of human hepatocytes with increasing concentrations of OSM resulted in a dose- and time-dependent decrease in CYP1A2 and CYP3A4 activities. As seen in figure 1, OSM had a maximal inhibitory effect on CYP1A2 (~55% of control) and CYP3A4 activity (70% of control) in the 25 to 50 units/ml range after 48 hr of continuous exposure to the cytokine.
|
|
Comparative effects of cytokines on the activity of different CYP enzymes in human hepatocytes. The ability of other cytokines to modulate CYP1A2 activity in primary cultures of human hepatocytes was compared with that of OSM. After 24 hr in culture, cells were incubated with increasing concentrations of OSM, IFN, IL-6, LIF, IL-11 and G-CSF, and CYP1A2 activity was measured 24 hr later. As seen in figure 3A, 50 units/ml OSM decreased CYP1A2 activity to 69% of control, whereas at same concentration the other cytokines caused a lower inhibition (83-97% of control). On the basis of the effects of the cytokines on CYP1A2 activity, 25 units/ml OSM, 100 units/ml IL-6, 100 units/ml LIF, 75 units/ml IL-11, 300 units/ml IFN and 320 units/ml G-CSF were selected for further experiments.
|
|
Effects of cytokines on the inducible expression of CYP isozymes in human hepatocytes. To analyze the effects of cytokines on MC-inducible CYP1A2 and DEX-inducible CYP3A4, 24-hr human hepatocytes were incubated with inducers and cytokines for an additional 48 hr. CYP1A2 activity increased after MC treatment (6-fold over noninduced controls). This induction was partially prevented when cytokines were present in the incubation media (fig. 4A). OSM and IFN were the most effective cytokines in preventing CYP1A2 induction by MC (43% and 68% of MC-treated hepatocytes respectively), whereas IL-11, LIF and G-CSF had no effects. De novo synthesis of CYP1A2 was studied in the same cultures. MC-treated cells increased the synthesis of CYP1A2. However, the synthesis of the enzyme dropped to the levels of uninduced cells in cultures where OSM or IFN was present (fig. 4B).
|
|
Maintenance of effects produced by OSM on CYP1A2 activity and protein synthesis. The maintenance of the signal produced by OSM was studied in two parallel sets of experiments in which kinetics of CYP1A2 activity and de novo synthesis were evaluated. After 24 hr of treatment with 25 units/ml OSM, human hepatocytes were either incubated in presence of the cytokine or shifted to control culture conditions for an additional period of time. The decrease in both CYP1A2 activity and protein synthesis produced by OSM was maintained for at least 72 hr after removing the cytokine from the culture medium (fig. 6). The time course of this effect was similar to that of the activity and protein synthesis reductions observed in cells continuously exposed to OSM.
|
Nitrite levels after hepatocytes exposure to cytokines. The possible role of induced nitric oxide biosynthesis in cytokines effects on the CYP system was examined. After nitric oxide production by hepatocytes, the accumulation of nitrite released into culture medium was measured. The results given in table 3 show that after 24 hr of treatment with cytokines, only IFN led to the induction of nitric oxide synthesis. None of the other cytokines produced alterations of nitrite levels in culture supernatant even after longer exposure periods (data not shown).
|
| |
Discussion |
|---|
|
|
|---|
Most information on drug metabolism impairment during inflammation
has been obtained in rodent in vivo or in vitro
models, and only a few studies have examined the effect of cytokines on human CYP expression (Abdel-Razzak et al., 1993
, 1994
;
Donato et al., 1993a
; Muntané-Relat et al.,
1995
). Most of these studies have focused on the effects of IFNs and
the major inflammatory cytokines, namely, IL-6, IL-
and TNF-
.
However, other cytokines, such as OSM, LIF, IL-11 and G-CSF, that are
released during the acute-phase response have not yet been tested for
their possible ability to influence the expression of human CYPs. In
the present report, we provide the first evidence that OSM can both
decrease basal CYP1A2 and CYP3A4 gene expression and strongly inhibit
induction by MC or DEX, respectively. This cytokine was used at a
concentration previously reported to mediate inhibition of albumin and
increase positive acute-phase protein secretion (haptoglobin,
1-antichymotrypsin and fibrinogen) in HepG2 cells and
rat hepatocytes (Richards et al., 1992
). These findings
complemented previous studies showing that IFN, TGF-
and
inflammatory cytokines (IL-6, IL-1
and TNF-
) depressed
CYP-associated drug metabolism in humans.
Although a general reduction in monooxygenase activity was derived from
cytokine treatment of human hepatocytes, marked differences in the
magnitude of the depression produced by each cytokine were found (fig.
3, table 2). OSM proved to be the most effective cytokine in reducing
all specific CYP activities. Its effects were even stronger than those
produced by IFN and IL-6, two cytokines with known inhibitory action on
human CYP gene expression in vitro (Donato et
al., 1993a
; Muntané-Relat et al., 1995
). Parallel to activity inhibition, decreases in de novo synthesis and
levels of CYP1A2 and CYP3A4 proteins also were observed (fig. 2). These results suggest that the alterations in monooxygenase activities observed after cytokine treatment could be due to decreases in enzyme
content.
The expression of CYP proteins can be regulated transcriptionally or
affected by processes altering the rate of protein stabilization and/or
degradation. RT-PCR analysis showed that OSM treatment produced a
down-regulation of the specific CYP1A2 and CYP3A4 mRNA that could
entirely account for the loss of CYP protein and activity observed at
the same time (fig. 2). The correlation of mRNA level, protein content
and monooxygenase activity reported in this study supports the
hypothesis that the down-regulation of CYP isozymes produced by OSM
occurs predominantly at the pretranslational level. Whether OSM reduced
CYP mRNA levels by interfering with the transcriptional activation of
the genes or by increasing the rate of degradation of the mRNAs is not
known. However, there is no reason to rule out the possibility that
cytokines negatively regulate CYP genes by similar mechanisms to those
involved in the induction of acute-phase genes. It is generally
accepted that cytokines involved in inflammatory response appear to
supress CYP gene expression largely by a transcriptional mechanism
(Barker et al., 1992
; Morgan et al., 1994
), but
other mechanisms may be involved. A decline in free heme content as a
result of the induction of heme oxygenase, a catabolic enzyme of the
heme group, seems to be an additional mechanism for the down-regulation
of IL-6-mediated CYP gene expression (Fukuda and Sassa, 1994
).
Inhibition of CYP by IFN via an increase in xanthine oxidase
activity and the generation of oxygen free radicals that subsequently
destroy CYP also were proposed (Ghezzi et al., 1985
). Recent
studies have pointed out that the inhibitory effects produced by IFN
and other inflammatory cytokines on CYP activities in rat (Stadler
et al., 1994
) and human (Donato et al., 1997
)
hepatocytes can be mediated by nitric oxide. This short-lived mediator
is synthesized by hepatocytes during inflammation in response to cytokines (Billiar et al., 1990
; Nussler et al.,
1992
). Our results showed that the only cytokine that significantly
induced nitric oxide release by human hepatocytes is IFN (table 3),
which suggests that the effects produced by OSM and the other cytokines
studied on the CYP system are not mediated by nitric oxide
biosynthesis.
Cytokines of the IL-6-related family that were studied in the present
work, such as OSM, LIF and IL-11, exhibit multiple functions and
redundancy in biological activities during the acute-phase reaction,
immune response, hematopoiesis and so on (Liu et al., 1992
;
Rose and Bruce, 1994
). On the basis of the results discussed above, we
suggest that another of the common biological actions of this cytokine
family is a general inhibition of expression of the CYPs. However, this
effect is particularly relevant in the case of OSM. The mechanism by
which cytokines negatively control CYP expression and other biological
activities remains unknown, but it has been suggested that it is
mediated by cytokine interactions with their respective plasmatic
receptors (Kishimoto, 1994
; Chen et al., 1995
; Tinel
et al., 1995
). Stimulation by these cytokines of their
specific receptors induces oligomerization and activation of receptor
components. Specific IL-6 family receptors become associated with a
common signal transducing receptor component, gp 130 (Kishimoto
et al., 1994
; Hibi et al., 1996
). The gp 130 protein serves as a signal transducer not only for the IL-6 cytokine but also for LIF, OSM, IL-11 and ciliary neurotrophic factor, which
suggests that it is the cause of the common biological functions that
these cytokines carry out in various tissues.
It is important to identify the mechanisms that mediate the decreases
in the capacity of the liver to metabolize drugs. The pharmacological
and toxicological implications of the profound alterations of
constitutive and inducible forms of CYPs produced by cytokines are
evident because the action on CYP functionality could impair the
elimination of drugs subsequently administered and alter their
therapeutic efficacy. When OSM effects on human hepatocytes are
considered in the context of events that occur during inflammation, it
seems conceivable that OSM could play an important role in the control
of the hepatic CYP system during the inflammatory process. This
potential in vivo down-regulation of CYP expression by OSM
could be mediated by two different mechanisms. First, by direct
interaction with its specific receptor (Mosley et al.,
1996
), activation of specific receptors of other related cytokines
(LIF; Gearing et al., 1992
) or regulation of the mRNA of the
IL-6 receptor (Geisterfer et al., 1995
). Second, it could also exert a cumulative indirect action on the CYP system in
vivo by increasing circulating levels of IL-6 via
action on vascular endothelial cells or fibroblasts (Brown et
al., 1991
; Richards and Agro, 1994
) for a wide variety of cell
types, including endothelial and fibroblasts cells that have a specific
receptor (Richards and Agro, 1994
). In addition, the biological signal
produced in vivo by OSM might be maintained in time for our
results show that OSM inhibition of CYP1A2 activity and protein
synthesis was maintained for at least 72 hr after incubation with OSM
ended (fig. 7). This effect contrasts
with our previous studies indicating that the effects of IFN, a
cytokine with a receptor that is not the same as the of the IL-6
receptor family, on CYP1A2 activity are transient, and enzyme activity
was fully restored 24 hr after IFN elimination from culture medium
(Donato et al., 1993a
). The potent activity shown by OSM in
the regulation of the human CYP system provides us with a good reason
for doing additional research into drug interactions and human liver
functionality.
| |
Acknowledgments |
|---|
The authors express their thanks to Dr. F. P. Guengerich (Center in Molecular Toxicology, Vanderbilt University, Nashville, TN) for providing anti-CYP1A2 and anti-CYP3A4 antibodies. The authors thank Dr. E. Offord for critical reading of this manuscript. The expert technical assistance of M. C. Lorenzo, T. Hualde and E. Belechón also is appreciated.
| |
Footnotes |
|---|
Accepted for publication December 15, 1997.
Received for publication June 30, 1997.
1 The financial support of European Union (Project AIR2-CT93-0860, BMH1-CT94-1097 and BIO4-CT96-0052) and the ALIVE Foundation is gratefully acknowledged.
Send reprint requests to: Dr. M. José Gómez-Lechón, Unidad de Hepatología Experimental, Centro de Investigación, Hospital Universitario La Fe, Avda. Campanar 21, Valencia-46009, Spain.
| |
Abbreviations |
|---|
CYP, cytochrome P450;
DEX, dexamethasone;
G-CSF, granulocyte colony-stimulating factor;
IFN, interferon-
;
IL-1
, interleukin-1
;
IL-6, interleukin-6;
IL-11, interleukin-11;
LIF, leukemia inhibitory factor;
MC, 3-methylcholanthrene;
OSM, oncostatin M;
RT, reverse transcriptase;
PCR, polymerase chain
reaction;
TGF-
, transforming growth factor-
;
TNF-
, tumor
necrosis factor-
.
| |
References |
|---|
|
|
|---|
1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture.
Mol Pharmacol
46:
1100-1110[Abstract].
-interferon administration on hepatic drug metabolism in mice.
Cancer Res
52:
262-266
supresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes.
J Biol Chem
267:
8050-8055
in human hepatocytes.
J Pharmacol Exp Ther
281:
484-490This article has been cited by other articles:
![]() |
A. E. Aitken and E. T. Morgan Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes Drug Metab. Dispos., September 1, 2007; 35(9): 1687 - 1693. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Q. Pham and A. Q. Pham Interaction potential between cranberry juice and warfarin Am. J. Health Syst. Pharm., March 1, 2007; 64(5): 490 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Donato, A. Lahoz, N. Jimenez, G. Perez, A. Serralta, J. Mir, J. V. Castell, and M. J. Gomez-Lechon Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts Drug Metab. Dispos., September 1, 2006; 34(9): 1556 - 1562. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Soucek, P. Anzenbacher, I. Skoumalova, and M. Dvorak Expression of Cytochrome P450 Genes in CD34+ Hematopoietic Stem and Progenitor Cells Stem Cells, September 1, 2005; 23(9): 1417 - 1422. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al. EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Congiu, M. L. Mashford, J. L. Slavin, and P. V. Desmond UDP Glucuronosyltransferase mRNA Levels in Human Liver Disease Drug Metab. Dispos., February 1, 2002; 30(2): 129 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rae, M. D. Johnson, M. E. Lippman, and D. A. Flockhart Rifampin Is a Selective, Pleiotropic Inducer of Drug Metabolism Genes in Human Hepatocytes: Studies with cDNA and Oligonucleotide Expression Arrays J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 849 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pan, Q. Xiang, and S. Ball Use of a Novel Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction Method to Study the Effects of Cytokines on Cytochrome P450 mRNA Expression in Mouse Liver Drug Metab. Dispos., June 1, 2000; 28(6): 709 - 713. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||